Successful treatment with low-dose decitabine in acute myelogenous leukemia in elderly patients over 80 years old: Five case reports

Lin,Jie; Zhu,Hongli; Li,Suxia; Fan,Hui; Lu,Xuechun; Chang,Cheng; Guo,Bo; Zhai,Bing

doi:10.3892/ol.2013.1139

Successful treatment with low-dose decitabine in acute myelogenous leukemia in elderly patients over 80 years old: Five case reports

Authors:
- Jie Lin
- Hongli Zhu
- Suxia Li
- Hui Fan
- Xuechun Lu
- Cheng Chang
- Bo Guo
- Bing Zhai
View Affiliations

Affiliations: Department of Geriatric Hematology, Chinese People's Liberation Army General Hospital, Haidian, Beijing 100853, P.R. China
Published online on: January 18, 2013 https://doi.org/10.3892/ol.2013.1139
Pages: 1321-1324

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of acute myelogenous leukemia (AML) in patients over 80 years old is >20 times greater than that observed in younger patients. Previously, no standard treatment protocol for elderly patients with AML existed, however the development of hypomethylating agents, including decitabine, has brought about promising results in AML. In the present study, we report on the usage of a lower than routine dosage of decitabine in patients over 80 years old with AML. Since January 2010, 5 patients diagnosed with AML over the age of 80 years old received treatment with decitabine in our hospital. Decitabine was administered at a dose of 10‑15 mg/m2 and repeated every other day for a total of 5 days. This cycle was repeated for ~6 weeks. The 5 patients received a total of 19 cycles of treatment with decitabine. No patient achieved complete or partial remission. An antileukemic effect was observed in 25% of courses (3/12). An increase in platelet count of >20x109/l was observed in 26.3% (5/19) of cycles compared with previous treatment. An increase in hemoglobin concentration of >20 g/l was observed in 36.8% (7/19) of cycles in comparison to previous treatment, four of which achieved normal hemoglobin levels. One patient became red blood cell transfusion‑independent. The median survival time was 19.8±4.8 months. Survival time from decitabine administration to mortality was 13.2±5.1 months. The main side-effect was bone marrow suppression with grade III‑IV thrombocytopenia, grade III‑IV leukocytopenia, grade III‑IV neutropenia and anemia accounting for 94.7% (18/19), 47.4% (9/19), 89.5% (17/19) and 21.1% (4/19), respectively. Severe infection or bleeding was not observed and no patient stopped treatment due to adverse effects. In conclusion, extremely low‑dose decitabine may be used safely in elderly patients and achieved longer survival times than reported previously in AML patients aged 80 and above. It is suggested that complete remission may not be the primary objective, while improvement of quality of life may be a better choice in AML patients over 80 years old. The cases observed in our study were limited, so more cases are required for further study.

View Figures

View References

1	Altekruse SF, Kosary CL, Krapcho M, et al: SEER Cancer Statistics Review, 1975–2007. Bethesda,MD: National Cancer Institute; 2010, Available at http://seer.cancer.gov/csr/1975_2007/.
2	Pagano L, Mele L, Casorelli I, et al: Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study. Haematologica. 85:1327–1329. 2000.PubMed/NCBI
3	Leith CP, Kopecky KJ, Godwin J, et al: Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 89:3323–3329. 1997.
4	Hiddemann W, Kern W, Schoch C, et al: Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 17:3569–3576. 1999.PubMed/NCBI
5	Wahlin A, Markevärn B, Golovleva I and Nilsson M: Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol. 115:25–33. 2001. View Article : Google Scholar : PubMed/NCBI
6	Gajewski JL, Ho WG, Nimer SD, et al: Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with preleukemic syndrome. J Clin Oncol. 7:1637–1645. 1989.PubMed/NCBI
7	Pedersen-Bjergaard J, Ersbøll J, Sørensen HM, et al: Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin’s lymphomas: comparison with results obtained in patients treated for Hodgkin’s disease and ovarian carcinoma with other alkylating agents. Ann Intern Med. 103:195–200. 1985.PubMed/NCBI
8	Kantarjian H, O’brien S, Cortes J, et al: Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer. 106:1090–1098. 2006.PubMed/NCBI
9	Lin J, Zhu HL, Lu XC, et al: Clinical analysis of 12 acute leukemia patients aged over 80 years. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 19:139–142. 2011.(In Chinese).
10	Bross PF, Beitz J, Chen G, et al: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 7:1490–1496. 2001.PubMed/NCBI
11	Kindler T, Breitenbuecher F, Marx A, et al: Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood. 103:3644–3654. 2004. View Article : Google Scholar : PubMed/NCBI
12	Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 20:2429–2440. 2002. View Article : Google Scholar : PubMed/NCBI
13	Lübbert M: DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol. 249:135–164. 2000.
14	Rüter B, Wijermans PW and Lübbert M: DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia. Int J Hematol. 80:128–135. 2004.PubMed/NCBI
15	Yu C, Rahmani M, Dent P and Grant S: The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res. 295:555–566. 2004. View Article : Google Scholar
16	Fiedler W, Mesters R, Tinnefeld H, et al: A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. 102:2763–2767. 2003. View Article : Google Scholar : PubMed/NCBI
17	Stirewalt DL and Radich JP: The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 3:650–665. 2003. View Article : Google Scholar : PubMed/NCBI
18	Marcucci G, Byrd JC, Dai G, et al: Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 101:425–432. 2003. View Article : Google Scholar : PubMed/NCBI
19	Zagonel V, Lo Re G, Marotta G, et al: 5-Aza-2′-deoxycytidine (decitabine) is an effective agent for the treatment of advanced myelodysplastic syndromes (MDS). Proc Am Soc Clin Oncol. 11:2261992.(abstr).
20	Pinto A and Zagonel V: 5-Aza-2′deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present, and future trends. Leukemia. 7(Suppl 1): 51–60. 1993.
21	Wijermans PW, Rüter B, Baer MR, et al: Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 32:587–591. 2008. View Article : Google Scholar : PubMed/NCBI
22	Issa JP, Gharibyan V, Cortes J, et al: Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 23:3948–3956. 2005. View Article : Google Scholar : PubMed/NCBI
23	Claus R and Lübbert M: Epigenetic targets in hematopoietic malignancies. Oncogene. 22:6489–6496. 2003. View Article : Google Scholar : PubMed/NCBI
24	Cashen AF, Schiller GJ, O’Donnell MR and DiPersio JF: Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 28:556–561. 2010. View Article : Google Scholar : PubMed/NCBI
25	Blum W, Garzon R, Klisovic RB, et al: Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 107:7473–7478. 2010. View Article : Google Scholar : PubMed/NCBI
26	Lübbert M, Rüter B, Claus R, et al: A multicenter phase II trial of decitabine as first-line treatment for older AML patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 97:393–401. 2012.PubMed/NCBI
27	Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al: Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood. 108:3271–3279. 2006.PubMed/NCBI
28	DeLima M, Ghaddar H, Pierce S and Estey E: Treatment of newly diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol. 93:89–95. 1996.PubMed/NCBI
29	Latagliata R, Alimena G, Carmosino I, et al: Conservative treatment for patients over 80 years with acute myelogenous leukemia. Am J Hematol. 71:256–259. 2002.PubMed/NCBI